NMTC vs. TELA, SRTS, ECOR, FONR, GUTS, LNSR, MLSS, MGRM, EDAP, and HYPR
Should you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include TELA Bio (TELA), Sensus Healthcare (SRTS), electroCore (ECOR), FONAR (FONR), Fractyl Health (GUTS), LENSAR (LNSR), Milestone Scientific (MLSS), Monogram Orthopaedics (MGRM), Edap Tms (EDAP), and Hyperfine (HYPR). These companies are all part of the "medical equipment" industry.
NeuroOne Medical Technologies vs.
NeuroOne Medical Technologies (NASDAQ:NMTC) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk.
In the previous week, NeuroOne Medical Technologies' average media sentiment score of 0.50 beat TELA Bio's score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.
TELA Bio has a consensus price target of $9.25, indicating a potential upside of 243.87%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts clearly believe TELA Bio is more favorable than NeuroOne Medical Technologies.
NeuroOne Medical Technologies received 4 more outperform votes than TELA Bio when rated by MarketBeat users. However, 74.68% of users gave TELA Bio an outperform vote while only 71.59% of users gave NeuroOne Medical Technologies an outperform vote.
NeuroOne Medical Technologies has higher earnings, but lower revenue than TELA Bio. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 94.4% of TELA Bio shares are held by institutional investors. 7.5% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 6.0% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
NeuroOne Medical Technologies has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, TELA Bio has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.
TELA Bio has a net margin of -60.49% compared to NeuroOne Medical Technologies' net margin of -356.76%. NeuroOne Medical Technologies' return on equity of -407.04% beat TELA Bio's return on equity.
Summary
TELA Bio beats NeuroOne Medical Technologies on 10 of the 17 factors compared between the two stocks.
Get NeuroOne Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroOne Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:NMTC) was last updated on 1/20/2025 by MarketBeat.com Staff
Free NMTC Stock Alerts